Autoimmune dementia
Identifying a possibly reversible course
Misdiagnosis of autoimmune dementia as an irreversible progressive neurodegenerative disorder may delay a correct diagnosis beyond the window of reversibility (6–12 months) and result in devastating consequences for the patient and family. Accurate diagnosis and early-initiated immunotherapy give patients the best possible outcome.
DEMENTIA Test menu
Dementia
Key testing
- DMC2 | Dementia, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid
- DMS2 | Dementia, Autoimmune/Paraneoplastic Evaluation, Serum
Advantages
- Uses a reflexive, algorithmic approach and multiple methodologies, including indirect immunofluorescence assay (IFA), cell-binding assay, immunoblot, radioimmunoassay, and Western blot to detect for nearly 20 neural antibodies associated with autoimmune dementia.
- Positive test results facilitate selection of targeted immunotherapies.
Highlights
Anastasia Zekeridou, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated panels and methodology boost the accuracy and efficiency of testing for three autoimmune neurology biomarkers. Early diagnosis is key to managing debilitating conditions associated with these antibodies.
Divyanshu Dubey, M.B.B.S., explains how Mayo Clinic Laboratories' unique PDE10A and TRIM46 tests facilitate the management of central nervous system disorders triggered by cancers. Early diagnosis and treatment are important for managing disabling neurological symptoms and malignancy.